Progyny Inc (PGNY)

Progyny (NASDAQ:PGNY) is presented as an affordable growth stock, combining strong earnings growth with reasonable valuation multiples and solid financial health. The article highlights its impressive EPS growth, attractive valuation ratios compared to its industry, and strong health and profitability ratings, including a debt-free balance sheet. While acknowledging potential risks like slowing revenue growth and a low gross margin, the analysis suggests PGNY offers a reasonable price for its projected earnings expansion.

JPMorgan Chase & Co. raised its price target for Progyny (NASDAQ:PGNY) to $30.00 from $27.00, maintaining a "neutral" rating and suggesting a 17.23% upside. This follows Progyny's strong quarterly earnings, beating expectations with $0.55 EPS on $350.51 million in revenue, and the authorization of a $200 million share repurchase program. The company currently holds a "Moderate Buy" consensus rating among analysts, with an average target price of $33.91.

Tocqueville Asset Management L.P. has acquired a new position in Progyny, Inc. (NASDAQ:PGNY), purchasing 84,000 shares valued at approximately $2.42 million. This comes as Progyny exceeded quarterly earnings and revenue expectations, reporting $0.55 EPS against a $0.33 consensus and $350.51 million in revenue, up 5.3% year over year. The company also authorized a $200 million share repurchase program and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $34.36.

Danske Bank A S recently acquired a new position in Progyny, Inc. (NASDAQ:PGNY), purchasing 528,717 shares valued at approximately $15.24 million in the second quarter. Other institutional investors also adjusted their holdings in Progyny, which has seen some insider selling of shares. Wall Street analysts currently rate Progyny as a "Moderate Buy" with an average price target of $34.36, and the company recently announced a $200 million share repurchase program.

Wells Fargo has initiated coverage on Progyny (PGNY) with an "Overweight" rating and a price target of $37.00. The stock is currently trading at $26.22, showing an 8.8% undervaluation according to GuruFocus's GF Value™, and holds a strong GF Score™ of 93/100, driven by excellent growth and valuation metrics. While guru ownership shows mixed activity and there has been some insider selling, the overall outlook suggests a promising investment opportunity for PGNY in the healthcare sector.